metformin has been researched along with Lymphoma, B-Cell in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Interestingly, we found that metformin could be used to potentiate the bortezomib-mediated cytotoxicity against PEL cells and to inhibit the activation of KSHV lytic cycle, a side effect of this treatment that resulted in a block of autophagy in these cells." | 1.46 | Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. ( Cirone, M; D'Orazi, G; Faggioni, A; Gilardini Montani, MS; Gonnella, R; Granato, M; Romeo, MA; Santarelli, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Granato, M | 1 |
| Gilardini Montani, MS | 1 |
| Romeo, MA | 1 |
| Santarelli, R | 1 |
| Gonnella, R | 1 |
| D'Orazi, G | 1 |
| Faggioni, A | 1 |
| Cirone, M | 1 |
| Sherman, MH | 1 |
| Kuraishy, AI | 1 |
| Deshpande, C | 1 |
| Hong, JS | 1 |
| Cacalano, NA | 1 |
| Gatti, RA | 1 |
| Manis, JP | 1 |
| Damore, MA | 1 |
| Pellegrini, M | 1 |
| Teitell, MA | 1 |
| Shi, WY | 1 |
| Xiao, D | 1 |
| Wang, L | 1 |
| Dong, LH | 1 |
| Yan, ZX | 1 |
| Shen, ZX | 1 |
| Chen, SJ | 1 |
| Chen, Y | 1 |
| Zhao, WL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin in Combination With R-CHOP for the First Line Treatment of Patients With Diffuse Large B-cell Lymphoma[NCT03200015] | Phase 2 | 15 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for metformin and Lymphoma, B-Cell
| Article | Year |
|---|---|
Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.
Topics: AMP-Activated Protein Kinase Kinases; Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proli | 2017 |
AID-induced genotoxic stress promotes B cell differentiation in the germinal center via ATM and LKB1 signaling.
Topics: Active Transport, Cell Nucleus; AMP-Activated Protein Kinase Kinases; Animals; Ataxia Telangiectasia | 2010 |
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Cycle; Cell Li | 2012 |